Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.01 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including oligodendrocyte progenitor cells; strongest in late spermatids | 0.75 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 113 | 0.91 |
| pathways Reactome | 1 pathway; mostly other | 0.30 |
No case: the score is under the bar. Receipt 10470
Sealed predictions
- FZD9 in oligodendrocytes, braakn/a → n/areceipt 10477
- FZD9 in dopamine neurons, braak-0.32 (p 0.400) → +0.04 (p 0.909)receipt 10478
Swarm cases
receipt 10478: FZD9 in dopamine neurons, braak
- power
- full sample -0.18 (p 0.476, n 18), 95% CI -0.60 to +0.31. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.21 (p 0.413, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.16 (p 0.538, n 18). could be the mix.
- skeptic
- leave-one-out range -0.35 to -0.09, sign flips 0; without severely affected donors -0.18 (p 0.476, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for FZD9 in dopamine neurons.
case closed: nothing better to follow up.
receipt 10477: FZD9 in oligodendrocytes, braak
- cell type
- FZD9 is not measured in oligodendrocytes; looking elsewhere.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for FZD9 in oligodendrocytes.
case closed: nothing better to follow up.
Receipts
loading the receipts